vs
Side-by-side financial comparison of COASTAL FINANCIAL CORP (CCB) and Twist Bioscience Corp (TWST). Click either name above to swap in a different company.
COASTAL FINANCIAL CORP is the larger business by last-quarter revenue ($138.0M vs $103.7M, roughly 1.3× Twist Bioscience Corp). On growth, Twist Bioscience Corp posted the faster year-over-year revenue change (16.9% vs -5.8%). COASTAL FINANCIAL CORP produced more free cash flow last quarter ($246.1M vs $-34.8M).
Fidelity National Financial, Inc., is an American provider of title insurance and settlement services to the real estate and mortgage industries. A Fortune 500 company, Fidelity National Financial generated approximately $8.469 billion in annual revenue in 2019 from its title and real estate-related operations. The company was the first instance of an attorney licensed by a Native American Tribe being certified as "authorized house counsel" in the state of Florida.
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
CCB vs TWST — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $138.0M | $103.7M |
| Net Profit | — | $-30.5M |
| Gross Margin | — | 52.0% |
| Operating Margin | 12.4% | -31.7% |
| Net Margin | — | -29.4% |
| Revenue YoY | -5.8% | 16.9% |
| Net Profit YoY | — | 3.4% |
| EPS (diluted) | $0.84 | $-0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $138.0M | $103.7M | ||
| Q3 25 | $144.7M | — | ||
| Q2 25 | $119.4M | — | ||
| Q1 25 | $139.5M | — | ||
| Q4 24 | $146.5M | — | ||
| Q3 24 | $151.1M | — | ||
| Q2 24 | $135.3M | — | ||
| Q1 24 | $148.4M | — |
| Q4 25 | — | $-30.5M | ||
| Q3 25 | $13.6M | — | ||
| Q2 25 | $11.0M | — | ||
| Q1 25 | $9.7M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $13.5M | — | ||
| Q2 24 | $11.6M | — | ||
| Q1 24 | $6.8M | — |
| Q4 25 | — | 52.0% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 12.4% | -31.7% | ||
| Q3 25 | 12.4% | — | ||
| Q2 25 | 12.0% | — | ||
| Q1 25 | 8.4% | — | ||
| Q4 24 | 11.7% | — | ||
| Q3 24 | 10.8% | — | ||
| Q2 24 | 11.1% | — | ||
| Q1 24 | 5.9% | — |
| Q4 25 | — | -29.4% | ||
| Q3 25 | 9.4% | — | ||
| Q2 25 | 9.2% | — | ||
| Q1 25 | 7.0% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 8.9% | — | ||
| Q2 24 | 8.6% | — | ||
| Q1 24 | 4.6% | — |
| Q4 25 | $0.84 | $-0.50 | ||
| Q3 25 | $0.88 | — | ||
| Q2 25 | $0.71 | — | ||
| Q1 25 | $0.63 | — | ||
| Q4 24 | $0.95 | — | ||
| Q3 24 | $0.97 | — | ||
| Q2 24 | $0.84 | — | ||
| Q1 24 | $0.50 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $197.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $491.0M | $456.1M |
| Total Assets | $4.7B | $638.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $197.9M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $491.0M | $456.1M | ||
| Q3 25 | $475.3M | — | ||
| Q2 25 | $461.7M | — | ||
| Q1 25 | $449.9M | — | ||
| Q4 24 | $438.7M | — | ||
| Q3 24 | $331.9M | — | ||
| Q2 24 | $316.7M | — | ||
| Q1 24 | $303.7M | — |
| Q4 25 | $4.7B | $638.1M | ||
| Q3 25 | $4.6B | — | ||
| Q2 25 | $4.5B | — | ||
| Q1 25 | $4.3B | — | ||
| Q4 24 | $4.1B | — | ||
| Q3 24 | $4.1B | — | ||
| Q2 24 | $4.0B | — | ||
| Q1 24 | $3.9B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $254.6M | $-24.8M |
| Free Cash FlowOCF − Capex | $246.1M | $-34.8M |
| FCF MarginFCF / Revenue | 178.3% | -33.5% |
| Capex IntensityCapex / Revenue | 6.1% | 9.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $436.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $254.6M | $-24.8M | ||
| Q3 25 | $59.0M | — | ||
| Q2 25 | $66.0M | — | ||
| Q1 25 | $71.7M | — | ||
| Q4 24 | $259.8M | — | ||
| Q3 24 | $62.6M | — | ||
| Q2 24 | $72.1M | — | ||
| Q1 24 | $56.8M | — |
| Q4 25 | $246.1M | $-34.8M | ||
| Q3 25 | $57.4M | — | ||
| Q2 25 | $64.0M | — | ||
| Q1 25 | $68.9M | — | ||
| Q4 24 | $249.9M | — | ||
| Q3 24 | $60.2M | — | ||
| Q2 24 | $69.5M | — | ||
| Q1 24 | $55.0M | — |
| Q4 25 | 178.3% | -33.5% | ||
| Q3 25 | 39.7% | — | ||
| Q2 25 | 53.6% | — | ||
| Q1 25 | 49.4% | — | ||
| Q4 24 | 170.6% | — | ||
| Q3 24 | 39.8% | — | ||
| Q2 24 | 51.3% | — | ||
| Q1 24 | 37.1% | — |
| Q4 25 | 6.1% | 9.6% | ||
| Q3 25 | 1.2% | — | ||
| Q2 25 | 1.7% | — | ||
| Q1 25 | 2.0% | — | ||
| Q4 24 | 6.8% | — | ||
| Q3 24 | 1.6% | — | ||
| Q2 24 | 1.9% | — | ||
| Q1 24 | 1.2% | — |
| Q4 25 | — | — | ||
| Q3 25 | 4.34× | — | ||
| Q2 25 | 5.99× | — | ||
| Q1 25 | 7.37× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 4.65× | — | ||
| Q2 24 | 6.22× | — | ||
| Q1 24 | 8.35× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CCB
| Other | $74.7M | 54% |
| Baa S Credit Enhancements | $47.3M | 34% |
| Baa S Program Income | $8.4M | 6% |
| Transaction Fees | $4.9M | 4% |
| Servicing And Other Baa S Fees | $1.6M | 1% |
| Baa S Fraud Enhancements | $1.1M | 1% |
TWST
| Industrial Chemicals | $37.2M | 36% |
| Diagnostics | $35.3M | 34% |
| Food Or Agriculture | $12.8M | 12% |
| Academic Research | $12.2M | 12% |
| Health Care | $6.1M | 6% |
